Natural History of Amyloid Deposition in Adults With Down Syndrome
| Status: | Completed |
|---|---|
| Conditions: | Other Indications |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 30 - Any |
| Updated: | 1/11/2019 |
| Start Date: | August 2009 |
| End Date: | March 31, 2018 |
The primary objective of this study is to assess the presence of amyloid in
non-demented/functionally stable adults with DS as a function of age, dividing the sample
into amyloid-positive and amyloid-negative groups. We will also obtain baseline cognitive
measures across a range of areas that are often affected by AD.
non-demented/functionally stable adults with DS as a function of age, dividing the sample
into amyloid-positive and amyloid-negative groups. We will also obtain baseline cognitive
measures across a range of areas that are often affected by AD.
Specific Aim 1: To assess and compare amyloid deposition (with PiB PET) in
non-demented/functionally stable adults with DS across three age cohorts (30-39, 40-49, and
>50 years of age).
Primary Hypothesis 1: At initial assessment, there will be a significantly higher prevalence
of amyloid-positive (PiB+) subjects in each succeeding age cohort.
In addition, we will test the following secondary hypothesis:
Secondary Aim 1: To compare the presence or absence of the apolipoprotein-E4 allele to the
retention of PiB in various brain areas of the DS subjects.
Secondary Hypothesis 1: At baseline, subjects who carry at least one Apolipoprotein-E4
(ApoE4) allele will show a higher prevalence of being PiB+.
non-demented/functionally stable adults with DS across three age cohorts (30-39, 40-49, and
>50 years of age).
Primary Hypothesis 1: At initial assessment, there will be a significantly higher prevalence
of amyloid-positive (PiB+) subjects in each succeeding age cohort.
In addition, we will test the following secondary hypothesis:
Secondary Aim 1: To compare the presence or absence of the apolipoprotein-E4 allele to the
retention of PiB in various brain areas of the DS subjects.
Secondary Hypothesis 1: At baseline, subjects who carry at least one Apolipoprotein-E4
(ApoE4) allele will show a higher prevalence of being PiB+.
Inclusion Criteria:
1. Participant IQ at least 47 (based upon Stanford-Binet V Abbrev. Test Battery)
2. Participant at least 30 years of age
3. DSDS score indicating participant is asymptomatic for AD
4. Reliable caregiver who is capable of providing correct information about the
participant's clinical symptoms and history
5. Agreement of caregiver and clinician that participant is able to cooperate with the
protocol tasks
6. Participant has provided assent (or consent) and/or parent/caregiver has provided
informed consent
Exclusion Criteria:
1. Participant is non-verbal or has extremely limited language skills
2. Score within the "symptomatic" range on the DSDS
3. Any significant disease or unstable medical condition that could affect
neuropsychological testing
4. Any problems with vision or hearing that could affect neuropsychological testing
5. Participants in whom MRI is contraindicated
6. Claustrophobia or prior failed experiences of completing MRI scans or blood draws
7. Participant is pregnant or breast feeding
8. History or other evidence of severe illness or other condition that would make the
participant, in the opinion of the investigator, unsuitable for the study?
We found this trial at
2
sites
Pittsburgh, Pennsylvania 15203
Principal Investigator: Benjamin L Handen, PhD
Phone: 412-235-5412
Click here to add this to my saved trials
Madison, Wisconsin 53705
Principal Investigator: Brad Christian, PhD
Phone: 608-262-4717
Click here to add this to my saved trials